Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: An analysis of clinical presentation and outcome in 144 patients

Cancer

Volumn 119, Issue 1, 2013, Pages 99-106

  Heilgeist, Andreas ^a   McClanahan, Fabienne ^a,b   Ho, Anthony D ^a   Witzens Harig, Mathias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

extranodal; Follicular Lymphoma International Prognostic Index; marginal zone lymphoma; mucosa associated lymphoid tissue; mucosa associated lymphoid tissue; nodal; prognosis; response; splenic; survival; treatment

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPLENECTOMY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872789106     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27704     Document Type: Article

References (30)

1. Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Braggio E, Dogan A, et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol. 2012; 25: 651-660.
3. Isaacson PG, Du MQ,. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004; 4: 644-653.
4. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004; 126: 43-49.
5. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG,. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338: 1175-1176.
6. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004; 96: 586-594.
7. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004; 350: 239-248.
8. Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003; 101: 2547-2550.
9. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008; 22: 487-495.
10. Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010; 116: 1479-1488.
11. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D,. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003; 120: 759-764.
12. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006; 107: 125-135.
13. Arcaini L, Lucioni M, Boveri E, Paulli M,. Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. Eur J Haematol. 2009; 83: 165-174.
14. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U,; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 (suppl 6): vi59-vi63.
15. Mazloom A, Medeiros LJ, McLaughlin PW, et al. Marginal zone lymphomas: factors that affect the final outcome. Cancer. 2010; 116: 4291-4298.
16. Perez-Encinas M, Villamayor M, Campos A, Gonzalez S, Bello JL,. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica. 1998; 83: 752-754.
17. Cheson BD, Horning SJ, Coiffieer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1244; erratum in J Clin Oncol. 2000;18:2351-2351.
18. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004; 104: 1258-1265.
19. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. J Clin Oncol. 1998; 16: 2825-2833.
20. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003; 102: 2741-2745.
21. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2011; 91: 543-551.
22. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009; 115: 5210-5217.
23. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725-3732.
24. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared with CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 405.
25. Papaxoinis G, Fountzilas G, Rontogianni D, et al. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2008; 19: 780-786.
26. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003; 101: 2489-2495.
27. Nathwani BN, Anderson JR, Armitge JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1999; 17: 2486-2492.
28. Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol. 2006; 85: 781-786.
29. Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007; 136: 301-304.
30. [No authors listed] A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987-994.